Comparative Pharmacology
Head-to-head clinical analysis: VENTAVIS versus YUTREPIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VENTAVIS versus YUTREPIA.
VENTAVIS vs YUTREPIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ventavis (iloprost) is a synthetic prostacyclin analog that causes vasodilation by increasing cyclic adenosine monophosphate (cAMP) levels in vascular smooth muscle cells, leading to relaxation and inhibition of platelet aggregation.
YUTREPIA (treprostinil) is a prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds and inhibits platelet aggregation. It binds to prostacyclin receptor (IP receptor), increasing cAMP in vascular smooth muscle cells, leading to vasodilation.
Inhaled: 2.5 mcg or 5 mcg via I-neb AAD system, 6 to 9 times daily (maximum 45 mcg/day). Titrate based on response and tolerability.
0.6 mg/kg intravenously over 15 minutes every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life: 0.45–1.0 hour (intravenous). Short half-life necessitates continuous intravenous or frequent nebulized administration for sustained effect.
Terminal elimination half-life: 12-15 hours (range 11-18 h) in adults; prolonged in renal impairment (CrCl <30 mL/min: up to 30 h).
Renal: ~6% as unchanged drug; biliary/fecal: minimal; extensive hepatic metabolism with metabolites primarily excreted in urine (50-60% of total clearance). No significant renal or biliary excretion of parent drug.
Renal: 80% as unchanged drug; fecal: 15% as metabolites; biliary: <5%.
Category C
Category C
Prostacyclin Analog
Prostacyclin Analog